C
CRINETICS PHARMACEUTICALS INC
NASDAQ: CRNX (Crinetics Pharmaceuticals, Inc.)
Last update: yesterday, 5:07PM50.39
-0.59 (-1.16%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bullish | Bullish |
Stockmoo Score
-0.1
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Paradigm Biocapital Advisors Lp | 30 Jun 2024 | 2,513,302 |
| Cormorant Asset Management, Lp | 30 Jun 2024 | 1,350,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 97.00 (Piper Sandler, 92.50%) | Buy |
| Median | 71.00 (40.90%) | |
| Low | 54.00 (JP Morgan, 7.16%) | Buy |
| Average | 73.25 (45.37%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 47.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Aug 2024 | 69.00 (36.93%) | Buy | 47.64 |
| 28 Jun 2024 | 60.00 (19.07%) | Buy | 44.79 | |
| Oppenheimer | 09 Aug 2024 | 73.00 (44.87%) | Buy | 47.64 |
| JP Morgan | 09 Jul 2024 | 54.00 (7.16%) | Buy | 48.23 |
| Piper Sandler | 02 Jul 2024 | 97.00 (92.50%) | Buy | 45.54 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BETZ STEPHEN F. | - | 53.12 | -3,000 | -159,360 |
| Aggregate Net Quantity | -3,000 | |||
| Aggregate Net Value ($) | -159,360 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 53.12 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BETZ STEPHEN F. | Officer | 26 Aug 2024 | Automatic sell (-) | 3,000 | 53.12 | 159,360 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |